Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BRTX 
BioRestorative Therapies Inc (BRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: BRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.57% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.53M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 2 | Beta -0.78 | 52 Weeks Range 1.19 - 2.55 | Updated Date 10/24/2025 |
52 Weeks Range 1.19 - 2.55 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1089.78% |
Management Effectiveness
Return on Assets (TTM) -66.42% | Return on Equity (TTM) -137.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1622758 | Price to Sales(TTM) 20.7 |
Enterprise Value -1622758 | Price to Sales(TTM) 20.7 | ||
Enterprise Value to Revenue 1.27 | Enterprise Value to EBITDA 0.13 | Shares Outstanding 7978117 | Shares Floating 5782699 |
Shares Outstanding 7978117 | Shares Floating 5782699 | ||
Percent Insiders 22.46 | Percent Institutions 7.95 |
Upturn AI SWOT
BioRestorative Therapies Inc
Company Overview
History and Background
BioRestorative Therapies, Inc. is a biotechnology company focused on stem cell therapies. Founded to develop and commercialize novel therapeutics for various diseases and conditions, the company has been involved in research and clinical trials involving stem cell technologies.
Core Business Areas
- Cardiocrineu2122 Program: Focuses on using autologous bone marrow-derived cells to treat chronic myocardial ischemia. A Phase 2 clinical trial is completed.
- ThermoStemu00ae Program: Involves using cultured autologous stem cells to treat chronic disc disease. Phase 2 clinical trial is ongoing.
Leadership and Structure
The leadership team consists of seasoned executives with experience in biotechnology and pharmaceuticals. Details regarding organizational structure beyond the C-suite are not readily available in public sources.
Top Products and Market Share
Key Offerings
- Cardiocrineu2122: A stem cell therapy designed to treat chronic myocardial ischemia. Market share data specific to Cardiocrineu2122 is unavailable. Competitors in the myocardial ischemia treatment space include pharmaceutical companies producing drugs and companies developing other interventional therapies.
- ThermoStemu00ae: A stem cell therapy designed to treat chronic disc disease. Market share data specific to ThermoStemu00ae is unavailable. Competitors in the chronic disc disease treatment space include companies offering pain management therapies, surgical solutions, and other regenerative medicine approaches.
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing rapid growth, driven by advancements in stem cell research and an increasing demand for novel therapies for chronic diseases and injuries.
Positioning
BioRestorative Therapies Inc is positioned within the regenerative medicine space as a developer of autologous stem cell therapies. Its competitive advantage lies in its proprietary cell culture and delivery technologies.
Total Addressable Market (TAM)
The total addressable market for regenerative medicine is projected to reach billions of dollars annually. BioRestorative Therapies Inc's positioning targets specific segments within this market, aiming to capture a share through clinical trial success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary cell culture technology
- Autologous stem cell approach (reduced risk of rejection)
- Clinical trials underway for lead product candidates
- Focus on underserved medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Regulatory hurdles in obtaining approvals
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive clinical trial results
- Advancements in stem cell research
Threats
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Clinical trial failures
- Economic downturn impacting research funding
Competitors and Market Share
Key Competitors
- MESO
- ATHX
- CRTX
Competitive Landscape
BioRestorative Therapies Inc competes with companies focused on regenerative medicine and stem cell therapies. Its advantages lie in its specific therapeutic targets and proprietary technologies, while its disadvantages include limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress rather than significant revenue generation.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals for its product candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for Cardiocrineu2122 and ThermoStemu00ae and seeking partnerships to support development efforts.
Summary
BioRestorative Therapies is a biotechnology company developing stem cell therapies. It is still in the clinical trial stage, and its success heavily relies on positive outcomes and subsequent regulatory approvals. Limited financial resources and competition pose challenges, but potential partnerships and further pipeline development offer opportunities. Strong research and development capabilities remain important.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. The AI-based rating is an opinion and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioRestorative Therapies Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2007-07-27 | Chairman of the Board, President & CEO Mr. Lance Alstodt | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://www.biorestorative.com |
Full time employees 11 | Website https://www.biorestorative.com | ||
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.